DOCSLIB.ORG

Safety and Tolerability of Nafamostat Mesilate And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Safety and Tolerability of Nafamostat Mesilate And bs_bs_banner Therapeutic Apheresis and Dialysis 2016; 20(2):197–204 doi: 10.1111/1744-9987.12357 © 2016 The Authors. Therapeutic Apheresis and Dialysis published by John Wiley & Sons Australia, Ltd on behalf of International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study Koji Sawada,1 Maiko Ohdo,1 Tomoko Ino,2 Takashi Nakamura,2 Toyoko Numata,2 Hiroshi Shibata,2 Jun-ichi Sakou,2 Masahiro Kusada,2 and Toshifumi Hibi3 1Dojima General & Gastroenterology Clinic, Osaka, 2Scientific and Technical Affairs Department, Japan Operation Division, Blood Purification Business Unit, Asahi Kasei Medical Co. Ltd., and 3Center for Advanced IBD Research and Treatment, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan Abstract: Nafamostat mesilate is the first anticoagulant of reactions (8.6% vs. 7.1%) and intrafilter pressure in- choice for leukocytapheresis (LCAP) with a Cellsorba E creases (12.7% vs. 16.8%) between the nafamostat column for treating ulcerative colitis (UC). However, mesilate and heparin groups. Adverse reactions of hemor- because of complications, mainly due to allergy to rhage or blood pressure decreases associated with heparin nafamostat mesilate, heparin may be used as a substitute. use were not observed. There were no significant differ- To evaluate the safety and tolerability of nafamostat ences in rates of clinical remission (69.1% vs. 68.1%) and mesilate and heparin as anticoagulants in LCAP for UC, mucosal healing (62.9% vs. 63.6%) between the we conducted post hoc analysis of data from a large- nafamostat mesilate and heparin groups. Thus, the safety scale, prospective, observational study of LCAP, which and tolerability were comparable in the nafamostat was conducted at 116 medical facilities in Japan between mesilate and heparin groups, indicating that both May 2010 and December 2012. Of 832 patients included nafamostat mesilate and heparin can be well tolerated as in this analysis, nafamostat mesilate and heparin were anticoagulants in LCAP for UC. Key Words: Anticoag- used in 676 (81.3%) and 113 (13.6%), respectively. There ulant, Heparin, Leukocytapheresis, Nafamostat mesilate, were no significant differences in the incidence of adverse Ulcerative colitis. Ulcerative colitis (UC) is a disease of unknown or- We established previously that leukocytapheresis igin that causes chronic inflammation in the mucosa (LCAP), a type of apheresis, is an effective treat- of the colon. The clinical symptoms are recurrent or ment for active UC (6,7). LCAP is an extracorpo- continuous diarrhea with bloody mucus in the stool, real circulation therapy that uses the Cellsorba E abdominal pain, and the presence of diffuse lesions column (Asahi Kasei Medical, Tokyo, Japan), that originate in the rectum and typically advance which is filled with a nonwoven polyester fiber that continuously in a proximal direction (1). removes activated leukocytes and activated plate- The main medical treatment for active UC is the lets from the peripheral blood to elicit anti- oral and topical administration of 5-aminosalicylic acid inflammatory effects (8–10). LCAP for active UC (5-ASA) (2); however, corticosteroids are often used received approval for medical insurance coverage in patients refractory to 5-ASA (3). Patients who are in Japan in 2001. also refractory to corticosteroids receive concurrent Our previous study revealed that the efficacy rate immunosuppressants or biological agents (4,5). of LCAP was 74% among 39 patients with steroid- resistant UC (6). In addition, the efficacy was 80% in a double-blind sham column control study of 19 Received March 2015; revised June 2015. patients with steroid-resistant active UC, which indi- Address correspondence and reprint requests to Dr. Koji Sawada, fi fi Dojima General & Gastroenterology Clinic, 2-4-27 Dojima, Kita-ku, cated that LCAP had a signi cantly higher ef cacy Osaka 530–0003, Japan. Email: [email protected] than a sham column (7). 197 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. 198 K Sawada et al. These studies used nafamostat mesilate, which has remove leukocytes. LCAP was performed 5–10 times a relatively short half-life, as the anticoagulant in the during the treatment period with a blood flow rate of LCAP treatment because UC is a hemorrhagic ill- 30–50 mL/min and a blood processing volume ness. In addition, polyester fiber has a negative elec- ≥30 mL/kg bodyweight. tric charge, which may induce the production of bradykinin in blood and thereby decrease blood Assessment of treatment outcomes pressure (11). Because nafamostat mesilate can in- The surveyed patient demographic data included hibit the production of bradykinin (12), it may be age, weight, gender, UC disease duration, response more suitable as an anticoagulant during LCAP to corticosteroids, and concomitant medications. treatment. However, several studies have reported The information from each LCAP session included that nafamostat mesilate is associated with adverse the date that LCAP was performed, the amount of events such as allergic symptoms and anaphylactic processed blood, the anticoagulant used, the reason shock (13,14). Thus, in an actual clinical setting, hep- for the change, the dose if the anticoagulant was arin could be used as a substitute anticoagulant in pa- changed, and the reason for discontinuation of tients who develop adverse events associated with LCAP where applicable. The following reasons for nafamostat mesilate. However, the tolerability of the discontinuation of LCAP were defined as heparin as an anticoagulant in LCAP for UC has “intrafilter pressure increase”: increased intrafilter not been investigated using data from a large-scale pressure or blood clotting. In addition, all adverse study. events noted during the observation period were re- We previously conducted a large-scale, prospec- corded in the CRFs, and any events for which a tive, observational study to evaluate the safety and causal relationship with LCAP could not be ruled efficacy of LCAP for active UC (15). In this large- out were considered adverse reactions (ARs) to scale study, nafamostat mesilate was used as the anti- LCAP. The AR terminology followed the Medical coagulant for LCAP treatment in 676 patients Dictionary for Regulatory Activities (MedDRA/J (81.3%), while heparin was used in 113 patients version 15.1). The incidence of all ARs and intrafilter (13.6%). Therefore, we analyzed the results of this pressure increases was investigated according to the study to evaluate the safety and tolerability of number of patients. nafamostat mesilate and heparin as anticoagulants The Lichtiger Clinical Activity Index (CAI) (16) in LCAP for UC. was used to determine efficacy and was assessed be- fore the start of LCAP and 2 weeks after the last PATIENTS AND METHODS LCAP session. Clinical remission was defined as a CAI score ≤4 at 2 weeks after the last LCAP session. In addition, clinical improvement was defined as clin- Study design ical remission or a final CAI score at least 50% lower The present study used data from a large-scale, than that obtained before the start of LCAP. Mucosal prospective, observational study of LCAP, which in- healing was assessed in all patients with an endo- cluded 847 patients with active UC (15). The study scopic index (EI) within the disease activity index was conducted in accordance with the Good (DAI) (17) and was defined as an EI of ≤1or0at Postmarketing Study Practice (GPSP) ordinance 2 weeks after the last LCAP session. The of the Japanese Ministry of Health, Labor, and hematochezia scores before the start of LCAP and Welfare. All patients in this study underwent LCAP 2 weeks after the last LCP session were compared at one of the 116 participating medical facilities be- for those patients with a DAI hematochezia score. tween May 2010 and December 2012. The treatment strategy for each patient, including the course of LCAP, was determined by the attending physician. Statistical analysis The observation period began 2 weeks prior to the Patient demographic data, the incidence of AR start of LCAP and ended 2 weeks following the and intrafilter pressure increases, and treatment effi- conclusion of treatment. The treating physicians cacy were compared by analyzing continuous data then filled out a case report form (CRF) after the using Wilcoxon rank-sum tests and categorical data observation period. using Fisher’s exact test. The hematochezia scores before and after treatment were compared using LCAP treatment Wilcoxon signed-rank test. Any missing data were Leukocytapheresis was performed using Cellsorba excluded. In all the analyses, P < 0.05 (two-sided) E, a column filled with nonwoven polyester fiber to was considered to be statistically significant. © 2016 The Authors. Therapeutic Apheresis and Dialysis published by John Wiley & Sons Australia, Ltd on behalf Ther Apher Dial, Vol. 20, No 2, 2016 of International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy Anticoagulants in LCAP for UC 199 RESULTS appropriate treatment. The main ARs in the heparin group were a decreased platelet count (2.7%, 3 of 113), nasal congestion (1.8%, 2 of 113), and pain in Anticoagulant use and demographic profiles the vascular access site (1.8%, 2 of 113). No serious Of the 847 patients enrolled in this study, the ARs, including exacerbated hemorrhagic stool or de- data from 832 were analyzed after 15 patients creased blood pressure, were observed. No ARs were excluded because the anticoagulant used fi were observed in the two patients who received could not be identi ed. The anticoagulants used LMWH in all sessions or in the five individuals who in the 832 patients are shown in Table 1.
Load more

Recommended publications
  • Empirical Treatment and Prevention of COVID-19
    Infect Chemother. 2020 Jun;52(2):e28 https://doi.org/10.3947/ic.2020.52.e28 pISSN 2093-2340·eISSN 2092-6448 Review Article Empirical Treatment and Prevention of COVID-19 Hyoung-Shik Shin Infectious Diseases Specialist, Korean Society of Zoonoses, Seoul, Korea Received: May 22, 2020 ABSTRACT Corresponding Author: Hyoung-Shik Shin, MD, PhD The rapid spread of severe acute respiratory coronavirus syndrome 2 (SARS-CoV-2) in the Infectious Diseases Specialist, Korean Society population and throughout the cells within our body has been developing. Another major of Zoonoses, 806, Seocho Town Trapalace, 23 cycle of coronavirus disease 2019 (COVID-19), which is expected in the coming fall, could Seocho-daero 74 gil, Seocho-gu, Seoul 06621, be even more severe than the current one. Therefore, effective countermeasures should be Korea. developed based on the already obtained clinical and research information about SARS- Tel: +82-10-8651-7617 E-mail: [email protected] CoV-2. The aim of this review was to summarize the data on the empirical treatment of COVID-19 acquired during this SARS-CoV-2 infection cycle; this would aid the establishment Copyright © 2020 by The Korean Society of an appropriate healthcare policy to meet the challenges in the future. The infectious of Infectious Diseases, Korean Society for disease caused by SARS-CoV-2 is characterized by common cold along with hypersensitivity Antimicrobial Therapy, and The Korean Society for AIDS reaction. Thus, in addition to treating common cold, it is essential to minimize the This is an Open Access article distributed exposure of cells to the virus and to mitigate the uncontrolled immune response.
    [Show full text]
  • Nafamostat Mesilate Improves Function Recovery After Stroke By
    Brain, Behavior, and Immunity xxx (2016) xxx–xxx Contents lists available at ScienceDirect Brain, Behavior, and Immunity journal homepage: www.elsevier.com/locate/ybrbi Full-length Article Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats ⇑ ⇑ Chenhui Li a, Jing Wang a, Yinquan Fang a, Yuan Liu a, Tao Chen a, Hao Sun a, Xin-Fu Zhou b, , Hong Liao a, a Jiangsu Key laboratory of Drug Screening, China Pharmaceutical University, 24 Tongjiaxiang Street, Nanjing 210009, China b School of Pharmacology and Medical Sciences, University of South Australia, Adelaide, SA 5000, Australia article info abstract Article history: Inflammation plays an important role in stroke pathology, making it a promising target for stroke inter- Received 7 January 2016 vention. Nafamostat mesilate (NM), a wide-spectrum serine protease inhibitor, is commonly used for Received in revised form 10 March 2016 treating inflammatory diseases, such as pancreatitis. However, its effect on neuroinflammation after Accepted 23 March 2016 stroke was unknown. Hence, the effects of NM on the inflammatory response post stroke were character- Available online xxxx ized. After transient middle cerebral artery occlusion (tMCAO) in rats, NM reduced the infarct size, improved behavioral functions, decreased the expression of proinflammatory mediators (TNF-a, IL-1b, Keywords: iNOS and COX-2) in a time-dependent manner and promoted the expression of different anti- Nafamostat mesilate inflammatory factors (CD206, TGF-b, IL-10 and IL-4) at different time points. Furthermore, NM could inhi- Stroke Inflammation bit the expression of proinflammatory mediators and promote anti-inflammatory mediators expression Thrombin in rat primary microglia following exposure to thrombin combined with oxygen–glucose deprivation Microglia (OGD).
    [Show full text]
  • Coagulation Factors Directly Cleave SARS-Cov-2 Spike and Enhance Viral Entry
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437960; this version posted April 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. Edward R. Kastenhuber1, Javier A. Jaimes2, Jared L. Johnson1, Marisa Mercadante1, Frauke Muecksch3, Yiska Weisblum3, Yaron Bram4, Robert E. Schwartz4,5, Gary R. Whittaker2 and Lewis C. Cantley1,* Affiliations 1. Meyer Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 2. Department of Microbiology and Immunology, Cornell University, Ithaca, New York, USA. 3. Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. 4. Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. 5. Department of Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, New York, NY, USA. *Correspondence: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437960; this version posted April 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Summary Coagulopathy is recognized as a significant aspect of morbidity in COVID-19 patients. The clotting cascade is propagated by a series of proteases, including factor Xa and thrombin. Other host proteases, including TMPRSS2, are recognized to be important for cleavage activation of SARS-CoV-2 spike to promote viral entry. Using biochemical and cell-based assays, we demonstrate that factor Xa and thrombin can also directly cleave SARS-CoV-2 spike, enhancing viral entry.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • New Trends, Advantages and Disadvantages in Anticoagulation and Coating Methods Used in Extracorporeal Life Support Devices
    membranes Review New Trends, Advantages and Disadvantages in Anticoagulation and Coating Methods Used in Extracorporeal Life Support Devices Anne Willers 1,2,*,†, Jutta Arens 3,† , Silvia Mariani 1,2 , Helena Pels 3, Jos G. Maessen 1,2, Tilman M. Hackeng 2,4, Roberto Lorusso 1,2 and Justyna Swol 5,* 1 ECLS Centre, Cardio-Thoracic Surgery, and Cardiology Department, Heart & Vascular Centre, Maastricht University Medical Centre (MUMC), P. Debyelaan 25, 6229 HX Maastricht, The Netherlands; [email protected] (S.M.); [email protected] (J.G.M.); [email protected] (R.L.) 2 Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands; [email protected] 3 Engineering Organ Support Technologies Group, Department of Biomechanical Engineering, Faculty of Engineering Technology, University of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands; [email protected] (J.A.); [email protected] (H.P.) 4 Department of Biochemistry, Faculty of Health, Medicine and Life, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands 5 Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, Ernst-Nathan Str. 1, 90419 Nuremberg, Germany * Correspondence: [email protected] (A.W.); [email protected] (J.S.); Tel.: +31-(0)649-07-9752 (A.W.); +49-(911)-398-0 (J.S.) † These authors contributed equally to this work. Citation: Willers, A.; Arens, J.; Mariani, S.; Pels, H.; Maessen, J.G.; Abstract: The use of extracorporeal life support (ECLS) devices has significantly increased in the Hackeng, T.M.; Lorusso, R.; Swol, J. last decades.
    [Show full text]
  • Overview of Planned Or Ongoing Studies of Drugs for the Treatment of COVID-19
    Version of 16.06.2020 Overview of planned or ongoing studies of drugs for the treatment of COVID-19 Table of contents Antiviral drugs ............................................................................................................................................................. 4 Remdesivir ......................................................................................................................................................... 4 Lopinavir + Ritonavir (Kaletra) ........................................................................................................................... 7 Favipiravir (Avigan) .......................................................................................................................................... 14 Darunavir + cobicistat or ritonavir ................................................................................................................... 18 Umifenovir (Arbidol) ........................................................................................................................................ 19 Other antiviral drugs ........................................................................................................................................ 20 Antineoplastic and immunomodulating agents ....................................................................................................... 24 Convalescent Plasma ...........................................................................................................................................
    [Show full text]
  • Nafamostat-Interferon-Alpha Combination Suppresses
    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.16.448653; this version posted June 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Nafamostat-interferon-alpha combination suppresses 2 SARS-CoV-2 infection in vitro and in vivo 3 Aleksandr Ianevski 1 *, Rouan Yao 1, Hilde Lysvand1, Gunnveig Grødeland 2,3,4, Nicolas Legrand 5, Tanel 4 Tenson 6, Magnar Bjørås 1, Denis E. Kainov 1,6,7 * 5 1 Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 6 7028, Trondheim, Norway 7 2 Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0372, Oslo, Norway 8 3 Institute of Clinical Medicine (KlinMed), University of Oslo, 0318, Oslo, Norway 9 4 Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, 0372, Oslo, 10 Norway 11 5 Oncodesign, 25 Avenue du Québec, 91140 Villebon Sur Yvette, France 12 6 Institute of Technology, University of Tartu, 50411 Tartu, Estonia 13 7 Institute for Molecular Medicine Finland, FIMM, University of Helsinki, 00014, Helsinki, Finland 14 * Corresponding author 15 16 SARS-CoV-2 and its vaccine/immune-escaping variants continue to pose a serious threat to public health 17 due to a paucity of effective, rapidly deployable, and widely available treatments. Here we address these 18 challenges by combining Pegasys (IFNa) and nafamostat to effectively suppress SARS-CoV-2 infection in cell 19 culture and hamsters.
    [Show full text]
  • Successful Conservative Treatment for Massive Uterine Bleeding with Non
    Kimura et al. BMC Women's Health (2020) 20:56 https://doi.org/10.1186/s12905-020-00924-8 CASE REPORT Open Access Successful conservative treatment for massive uterine bleeding with non-septic disseminated intravascular coagulation after termination of early pregnancy in a woman with huge adenomyosis: case report Fuminori Kimura*, Akimasa Takahashi, Jun Kitazawa, Fumi Yoshino, Daisuke Katsura, Tsukuru Amano and Takashi Murakami Abstract Background: Adenomyosis is a benign gynecological condition in which endometrial tissue or endometrial-like tissue develops within the uterine myometrium. Few cases of disseminated intravascular coagulation has been reported in the patients with adenomyosis. Although hysterectomy is indicated for refractory massive uterine bleeding in the patients with advanced uterine adenomyosis, conservative treatment is often desired in women in the late reproductive age. Recently such cases are increasing due to the social trend of late marriage. (Continued on next page) * Correspondence: [email protected] Department of Obstetrics and Gynecology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
    [Show full text]
  • Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing Or Completed Randomized Trials
    medRxiv preprint doi: https://doi.org/10.1101/2021.01.04.21249227; this version posted January 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials Azita H. Talasaz, PharmD,1, 2 Parham Sadeghipour, MD,3 Hessam Kakavand, PharmD,1, 2 Maryam Aghakouchakzadeh, PharmD,1 Elaheh Kordzadeh-Kermani, PharmD,1 Benjamin W. Van Tassell, PharmD,4, 5 Azin Gheymati, PharmD,1 Hamid Ariannejad, MD,2 Seyed Hossein Hosseini, PharmD,1 Sepehr Jamalkhani, MD(2021),3 Michelle Sholzberg, MDCM, MSc,6, 7 Manuel Monreal, MD, PhD,8 David Jimenez, MD, PhD,9 Gregory Piazza, MD, MS,10 Sahil A. Parikh, MD,11, 12 Ajay J. Kirtane, MD, SM,11, 12 John W. Eikelboom, MBBS,13 Jean M. Connors, MD,14 Beverley J. Hunt, MD,15 Stavros V. Konstantinides MD, PhD,16, 17 Mary Cushman, MD, MSc18, 19 Jeffrey I. Weitz, MD,20, 21 Gregg W. Stone, MD,11, 22 Harlan M. Krumholz, MD, SM,23, 24, 25 Gregory Y.H. Lip, MD,26, 27 Samuel Z. Goldhaber, MD,10 and Behnood Bikdeli, MD, MS, 10, 11, 23, * Total Words Count: 9020 (including text, tables, Figure legends, but not online supplement) Affiliations: 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. 2. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. 3. Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
    [Show full text]
  • Circulating Activated Protein C Levels Are Not Increased in Septic Patients
    Arishima et al. Thrombosis Journal (2018) 16:24 https://doi.org/10.1186/s12959-018-0178-0 RESEARCH Open Access Circulating activated protein C levels are not increased in septic patients treated with recombinant human soluble thrombomodulin Takuro Arishima1†, Takashi Ito1,2*† , Tomotsugu Yasuda1†, Nozomi Yashima3, Hiroaki Furubeppu1, Chinatsu Kamikokuryo3, Takahiro Futatsuki1, Yutaro Madokoro1, Shotaro Miyamoto1, Tomohiro Eguchi1, Hiroyuki Haraura1, Ikuro Maruyama2 and Yasuyuki Kakihana1,3 Abstract Background: Recombinant human soluble thrombomodulin (rTM) has been used for the treatment of disseminated intravascular coagulation in Japan, and an international phase III clinical trial for rTM is currently in progress. rTM mainly exerts its anticoagulant effects through an activated protein C (APC)-dependent mechanism, but the circulating APC levels after rTM treatment have not been clarified. This prospective observational study investigated plasma APC levels after rTM treatment. Methods: Plasma levels of soluble thrombomodulin, thrombin-antithrombin complex (TAT), protein C, and APC were measured in eight septic patients treated with rTM. APC generation in vitro was assessed in the presence or absence of rTM. Results: rTM significantly increased thrombin-mediated APC generation in vitro. In septic patients, soluble thrombomodulin levels were significantly increased during a 30–60-min period of rTM treatment and TAT levels were decreased. However, APC activity was not increased during the treatment period. Conclusions: Plasma APC activity is not increased in septic patients treated with rTM. It is possible that APC acts locally and does not circulate systemically. Keywords: Disseminated intravascular coagulation, Protein C, Sepsis, Thrombomodulin Background can be compromised, leading to sepsis-associated dissemi- Thrombomodulin is an anticoagulant protein expressed on nated intravascular coagulation (DIC) [3].
    [Show full text]
  • RCR05: Nafamostat
    EUnetHTA Joint Action 3 WP4 “Rolling Collaborative Review” of Covid-19 treatments NAFAMOSTAT FOR THE TREATMENT OF COVID-19 Project ID: RCR05 Monitoring Report Version 6.0, February 2021 Template version November 2020 This Rolling Collaborative Review Living Document is part of the project / joint action ‘724130 / EUnetHTA JA3’ which has received funding from the European Union’s Health Programme (2014-2020) Dec2015 ©EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 Rolling Collaborative Review - Living Report RCR05 – Nafamostat for the treatment of COVID-19 DOCUMENT HISTORY AND CONTRIBUTORS Version Date Description of changes V 1.0 14/08/2020 First version, search includes grey literature and contacts with authors and trial investigators. V 2.0 15/09/2020 Second version V 3.0 15/10/2020 Third version V 4.0 16/11/2020 Fourth version V 5.0 15/12/2020 Fifth version V 6.0 15/02/2021 Sixth version Major changes from previous version Chapter, page no. Major changes from version 5.0 Tables with trials, More trials, planned and ongoing, have been added; trial contact, design and p. 12 ff. recruitment status were updated Disclaimer The content of this “Rolling Collaborative Review” (RCR) represents a consolidated view based on the consensus within the Authoring Team; it cannot be considered to reflect the views of the European Network for Health Technology Assessment (EUnetHTA), EUnetHTA’s participating institutions, the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.
    [Show full text]
  • TMPRSS2 Inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat As Potential Treatments for COVID-19
    TMPRSS2 inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat as potential treatments for COVID-19. Author Arsalan Azimi1 Correspondence [email protected] Abstract In December 2019 SARS-CoV-2 emerged in Wuhan, China, leading to a pandemic in March 2020. Although clinical presentation of COVID-19 ranges from no symptoms to acute respiratory and multiorgan failure, the vast majority of the patients only experience flu-like symptoms. However because of highly contagious nature of the disease, overall COVID-19 is considered a global health burden. Since ACE2, TMPRSS2 expressing cells are the potential hosts for the virus, inhibiting TMPRSS2 by clinically proven protease inhibitors Bromhexine, Aprotinin, Camostat and Nafamostat are suggested as potential treatments for COVID-19. Keywords SARS-CoV-2, COVID-19, Pathophysiology, Pharmacology, TMPRSS2 inhibitor, Bromhexine, Aprotinin, Camostat, Nafamostat Highlights –SARS-CoV-2 infects ACE2, TMPRSS2 expressing cells –Inhibiting TMPRSS2 hinders infection of host cells with SARS-CoV-2 –Bromhexine, Aprotinin, Camostat and Nafamostat inhibit TMPRSS2 –Bromhexine, Aprotinin, Camostat and Nafamostat may contribute to treatment of COVID- 19 1. Shiraz University of Medical Sciences, Zand Blvd, Shiraz, 71345-1978, Iran. Correspondence: [email protected] Introduction Coronavirus disease 2019 (COVID-19) is an illness that is caused by Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) (Zheng et al.,2020; Wu and McGoogan 2020). In December 2019 SARS-CoV-2 emerged in Wuhan, China and thereafter spread throughout the world and in March 11, 2020, World Health Organization declared COVID-19 a pandemic (Zheng et al., 2020; Wu and McGoogan 2020). Currently, COVID-19 seems to transmit from person to person via respiratory droplets (Wu and McGoogan 2020).
    [Show full text]